Peter Michaely
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Peter Michaely has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Zhenze Zhao
Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX
7 shared publicationsHongyun Dong
Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX
3 shared publicationsShanica Pompey
Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, United States
3 shared publications- Dana Kim Reed
Department of Cell Biology, University of Texas Southwestern Medical Center, TX
2 shared publications - Diana R. Tomchick
Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, USA
2 shared publications Jian Weng
Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, United States
2 shared publications
Latest Publications
- Open Access
- 10 June 2020
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 219 (9)
Wbox2: A clathrin terminal domain–derived peptide inhibitor of clathrin-mediated endocytosis
Clathrin-mediated endocytosis (CME) occurs via the formation of clathrin-coated vesicles from clathrin-coated pits (CCPs). Clathrin is recruited to CCPs through interactions between the AP2 complex and its N-terminal domain, which in turn recruits endocytic accessory proteins. Inhibitors of CME that interfere with clathrin function have been described, but their specificity and mechanisms of action are unclear. Here we show that overexpression of the N-terminal domain with (TDD) or without (TD) the distal leg inhibits CME and CCP dynamics by perturbing clathrin interactions with AP2 and SNX9. TDD overexpression does not affect clathrin-independent endocytosis or, surprisingly, AP1-dependent lysosomal trafficking from the Golgi. We designed small membrane–permeant peptides that encode key functional residues within the four known binding sites on the TD. One peptide, Wbox2, encoding residues along the W-box motif binding surface, binds to SNX9 and AP2 and potently and acutely inhibits CME.
- 10 June 2020
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 219 (9)
Open AccessWbox2: A clathrin terminal domain–derived peptide inhibitor of clathrin-mediated endocytosis
Clathrin-mediated endocytosis (CME) occurs via the formation of clathrin-coated vesicles from clathrin-coated pits (CCPs). Clathrin is recruited to CCPs through interactions between the AP2 complex and its N-terminal domain, which in turn recruits endocytic accessory proteins. Inhibitors of CME that interfere with clathrin function have been described, but their specificity and mechanisms of action are unclear. Here we show that overexpression of the N-terminal domain with (TDD) or without (TD) the distal leg inhibits CME and CCP dynamics by perturbing clathrin interactions with AP2 and SNX9. TDD overexpression does not affect clathrin-independent endocytosis or, surprisingly, AP1-dependent lysosomal trafficking from the Golgi. We designed small membrane–permeant peptides that encode key functional residues within the four known binding sites on the TD. One peptide, Wbox2, encoding residues along the W-box motif binding surface, binds to SNX9 and AP2 and potently and acutely inhibits CME.
- Open Access
Structure-based inhibitors reveal roles for the clathrin terminal domain and its W-box binding site in CME
Clathrin-mediated endocytosis (CME) occurs via the formation of clathrin-coated vesicles from clathrin-coated pits (CCPs). Clathrin is recruited to CCPs through interactions between the AP2 complex and its N-terminal domain (TD), which in turn recruits endocytic accessory proteins. Inhibitors of CME that interfere with clathrin function have been described, but their specificity and mechanisms of action are unclear. Here we show that overexpression of the TD with or without the distal leg specifically inhibits CME and CCP dynamics by perturbing clathrin interactions with AP2 and SNX9. We designed small membrane-penetrating peptides that mimic the four known binding sites on the TD. A peptide, Wbox2, designed to mimic to the W-box motif binding surface on TD binds to SNX9 and AP2, and potently and acutely inhibits CME, while not perturbing AP1-dependent lysosomal trafficking from the Golgi or bulk, fluid phase endocytosis. Summary: Chen et al define the role the N-terminal domain (TD) of clathrin heavy chain in early and late stages of clathrin-mediated endocytosis, and guided by its structure, design a membrane-penetrating peptide, Wbox2, that acutely and potently inhibits CME.
Open AccessStructure-based inhibitors reveal roles for the clathrin terminal domain and its W-box binding site in CME
Clathrin-mediated endocytosis (CME) occurs via the formation of clathrin-coated vesicles from clathrin-coated pits (CCPs). Clathrin is recruited to CCPs through interactions between the AP2 complex and its N-terminal domain (TD), which in turn recruits endocytic accessory proteins. Inhibitors of CME that interfere with clathrin function have been described, but their specificity and mechanisms of action are unclear. Here we show that overexpression of the TD with or without the distal leg specifically inhibits CME and CCP dynamics by perturbing clathrin interactions with AP2 and SNX9. We designed small membrane-penetrating peptides that mimic the four known binding sites on the TD. A peptide, Wbox2, designed to mimic to the W-box motif binding surface on TD binds to SNX9 and AP2, and potently and acutely inhibits CME, while not perturbing AP1-dependent lysosomal trafficking from the Golgi or bulk, fluid phase endocytosis. Summary: Chen et al define the role the N-terminal domain (TD) of clathrin heavy chain in early and late stages of clathrin-mediated endocytosis, and guided by its structure, design a membrane-penetrating peptide, Wbox2, that acutely and potently inhibits CME.
- Open Access
- 1 February 2017
- Published by Elsevier in Journal of Lipid Research
- Vol. 58 (2) , 364-374
Identification of roles for H264, H306, H439, and H635 in acid-dependent lipoprotein release by the LDL receptor
- 1 February 2017
- Published by Elsevier in Journal of Lipid Research
- Vol. 58 (2) , 364-374
Open AccessIdentification of roles for H264, H306, H439, and H635 in acid-dependent lipoprotein release by the LDL receptor
- Open Access
- 24 September 2013
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 2, e00905
Cavin-3 dictates the balance between ERK and Akt signaling
Cavin-3 is a tumor suppressor protein of unknown function. Using both in vivo and in vitro approaches, we show that cavin-3 dictates the balance between ERK and Akt signaling. Loss of cavin-3 increases Akt signaling at the expense of ERK, while gain of cavin-3 increases ERK signaling at the expense Akt. Cavin-3 facilitates signal transduction to ERK by anchoring caveolae to the membrane skeleton of the plasma membrane via myosin-1c. Caveolae are lipid raft specializations that contain an ERK activation module and loss of the cavin-3 linkage reduces the abundance of caveolae, thereby separating this ERK activation module from signaling receptors. Loss of cavin-3 promotes Akt signaling through suppression of EGR1 and PTEN. The in vitro consequences of the loss of cavin-3 include induction of Warburg metabolism (aerobic glycolysis), accelerated cell proliferation, and resistance to apoptosis. The in vivo consequences of cavin-3 knockout are increased lactate production and cachexia.
- 24 September 2013
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 2, e00905
Open AccessCavin-3 dictates the balance between ERK and Akt signaling
Cavin-3 is a tumor suppressor protein of unknown function. Using both in vivo and in vitro approaches, we show that cavin-3 dictates the balance between ERK and Akt signaling. Loss of cavin-3 increases Akt signaling at the expense of ERK, while gain of cavin-3 increases ERK signaling at the expense Akt. Cavin-3 facilitates signal transduction to ERK by anchoring caveolae to the membrane skeleton of the plasma membrane via myosin-1c. Caveolae are lipid raft specializations that contain an ERK activation module and loss of the cavin-3 linkage reduces the abundance of caveolae, thereby separating this ERK activation module from signaling receptors. Loss of cavin-3 promotes Akt signaling through suppression of EGR1 and PTEN. The in vitro consequences of the loss of cavin-3 include induction of Warburg metabolism (aerobic glycolysis), accelerated cell proliferation, and resistance to apoptosis. The in vivo consequences of cavin-3 knockout are increased lactate production and cachexia.
- Open Access
- 1 June 2013
- Published by Elsevier in Journal of Lipid Research
- Vol. 54 (6) , 1550-1559
S-nitrosylation of ARH is required for LDL uptake by the LDL receptor
- 1 June 2013
- Published by Elsevier in Journal of Lipid Research
- Vol. 54 (6) , 1550-1559
Open AccessS-nitrosylation of ARH is required for LDL uptake by the LDL receptor
- Open Access
- 1 March 2013
- Published by Elsevier in Journal of Lipid Research
- Vol. 54 (3) , 744-753
Quantitative fluorescence imaging reveals point of release for lipoproteins during LDLR-dependent uptake
- 1 March 2013
- Published by Elsevier in Journal of Lipid Research
- Vol. 54 (3) , 744-753
Open AccessQuantitative fluorescence imaging reveals point of release for lipoproteins during LDLR-dependent uptake
- 20 June 2012
- Published by Elsevier in Experimental Cell Research
- Vol. 318 (16) , 2128-2142
Sterol-dependent nuclear import of ORP1S promotes LXR regulated trans-activation of apoE
- 20 June 2012
- Published by Elsevier in Experimental Cell Research
- Vol. 318 (16) , 2128-2142
Sterol-dependent nuclear import of ORP1S promotes LXR regulated trans-activation of apoE
- 9 April 2011
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
- Vol. 1811 (6) , 397-408
Role of an intramolecular contact on lipoprotein uptake by the LDL receptor
- 9 April 2011
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
- Vol. 1811 (6) , 397-408
Role of an intramolecular contact on lipoprotein uptake by the LDL receptor
- 30 June 2009
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 48 (30) , 7313-7324
The Role of Calcium in Lipoprotein Release by the Low-Density Lipoprotein Receptor
The LDL receptor (LDLR) mediates efficient endocytosis of VLDL, VLDL remnants, and LDL. As part of the uptake process, the LDLR releases lipoproteins in endosomes. Released lipoproteins are subsequently trafficked to lysosomes for degradation, while the LDLR recycles back to the cell surface for further rounds of uptake. Endosomes have at least two features that can promote lipoprotein release: an acidic pH and low concentrations of free calcium. The relative contributions of acidic pH and low free calcium to lipoprotein release are not known. Here, we generated fibroblasts that express either normal LDLR or an LDLR variant that is unable to employ the acid-dependent release mechanism to determine the relative contributions of acidic pH and low free calcium on lipoprotein release. We show that endosomal concentrations of free calcium can drive lipoprotein release at rates that are similar to those of acid-dependent release and that the calcium-dependent and acid-dependent mechanisms can cooperate during lipoprotein release. Assessment of lipoprotein uptake by these two cell lines showed that LDL uptake requires the acid-dependent mechanism, while uptake of the VLDL remnant, β-VLDL, does not. We propose that endosomes use both the acid-dependent and calcium-dependent release mechanisms to drive lipoprotein release and that the acid-dependent process is only required for LDL release.
- 30 June 2009
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 48 (30) , 7313-7324
The Role of Calcium in Lipoprotein Release by the Low-Density Lipoprotein Receptor
The LDL receptor (LDLR) mediates efficient endocytosis of VLDL, VLDL remnants, and LDL. As part of the uptake process, the LDLR releases lipoproteins in endosomes. Released lipoproteins are subsequently trafficked to lysosomes for degradation, while the LDLR recycles back to the cell surface for further rounds of uptake. Endosomes have at least two features that can promote lipoprotein release: an acidic pH and low concentrations of free calcium. The relative contributions of acidic pH and low free calcium to lipoprotein release are not known. Here, we generated fibroblasts that express either normal LDLR or an LDLR variant that is unable to employ the acid-dependent release mechanism to determine the relative contributions of acidic pH and low free calcium on lipoprotein release. We show that endosomal concentrations of free calcium can drive lipoprotein release at rates that are similar to those of acid-dependent release and that the calcium-dependent and acid-dependent mechanisms can cooperate during lipoprotein release. Assessment of lipoprotein uptake by these two cell lines showed that LDL uptake requires the acid-dependent mechanism, while uptake of the VLDL remnant, β-VLDL, does not. We propose that endosomes use both the acid-dependent and calcium-dependent release mechanisms to drive lipoprotein release and that the acid-dependent process is only required for LDL release.
- Open Access
- 1 March 2009
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 284 (11) , 6982-6987
Localization and Structure of the Ankyrin-binding Site on β2-Spectrin
- 1 March 2009
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 284 (11) , 6982-6987
Open AccessLocalization and Structure of the Ankyrin-binding Site on β2-Spectrin